Spero Therapeutics, Inc. Cash Flow Statement
SPRO|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Spero Therapeutics, Inc. used $23M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$68.6M | $22.8M | -$46.4M | -$89.8M | -$78.3M | -$60.9M | -$41.7M | -$25.5M |
| Depreciation & Amortization | $2.0K | $367.0K | $869.0K | $646.0K | $761.0K | $750.0K | $409.0K | $279.0K |
| Operating Cash Flow | -$23.4M | -$33.0M | -$7.7M | -$64.3M | -$85.9M | -$50.0M | -$39.6M | -$29.0M |
| Capital Expenditures | - | - | - | - | - | $314.0K | $2.4M | $830.0K |
| Free Cash Flow | - | - | - | - | - | -$50.3M | -$42.1M | -$29.8M |
| FCF Margin | - | - | - | - | - | -277.4% | -1060.5% | -8892.2% |